期刊文献+

帕利哌酮缓释片对急性期精神分裂症患者社会功能的影响 被引量:4

Efficacy of paliperidone extended-release tablets on improving social function in acute patients with schizophrenia
原文传递
导出
摘要 目的比较帕利哌酮缓释片与常用经典和非经典抗精神病药对急性期精神分裂症患者社会功能的影响。方法将154例患者分为经典抗精神病药治疗组(经典组44例)、非经典抗精神病药治疗组(非经典组57例)及帕利哌酮缓释片治疗组(53例),分别于入组时和治疗后第4、12、24周末采用阳性与阴性症状量表(positive andnegative symptoms scale,PANSS)和个人与社会表现量表(personal and social performance scale,PSP)进行评定。结果治疗后第4周末帕利哌酮组PANSS各因子分及总分均低于非经典组,非经典组低于经典组,差异有统计学意义(P<0.05或P<0.01)。第12和24周末,帕利哌酮组与非经典组阴性症状分及总分低于经典组,差异有统计学意义(P<0.05)。治疗后帕利哌酮组PSP评分高于非经典组,更高于经典组,差异有统计学意义(P<0.01)。结论急性期用药能改善患者的精神症状及社会功能,非经典抗精神病药物,尤其是帕利哌酮缓释片,优于经典抗精神病药物。 Objective To compare the effects of paliperidone extended-release (paliperidone ER) tablets with commonly used typical and atypical antipsychotic drugs on social function in acute patients with schizophrenia. Methods A total of 154 patients were divided into three treatment groups: the typical antipsychotics group ( "Typical Group" ), the atypical antipsychotics group (" Atypical Group") and the paliperidone extended-release tablets group (" Paliperidone Group" ). All patients were assessed with the Positive and Negative Symptoms scale ( PANSS ), and the Personal and Social Performance scale (PSP) before and after each treatment regime. Results At the end of the 4th week of treatment, the Paliperidone Group had significantly lower scores for both total and sub-factors on PANSS than the Atypical Group, and the latter had lower scores than the Typical Group ( P 〈 0.01 or P 〈 0.05 ). At the ends of the 12th and 24th week of treatment,the Atypical Group and the Paliperidone Group both had significantly lower total scores and negative symptom scores than the Typical Group( P 〈0.05 or P 〈0.01 ). Assessed with the PSP at the ends of the 4th, 12th and 24th week, the Paliperidone Group scored significantly higher than the Atypical Group ( P 〈 0.01 ), and even higher than the Typical Group ( P 〈 0.05). Conclusion Psychotic symptoms and social function can be improved with antipsychotic drugs in the acute phase of schizophrenia patients, and atypical antipsychotics, especially paliperidone ER are superior to typical antipsychotics.
出处 《山东大学学报(医学版)》 CAS 北大核心 2011年第8期100-103,共4页 Journal of Shandong University:Health Sciences
关键词 精神分裂症 抗精神病药物 社会功能 急性期 Schizophrenia Antipsychotic drugs Social function Acute
  • 相关文献

参考文献11

  • 1Jones P B, Barnes T R, Davies L. Randomized controlled trial of the effect on quality of life of second-vs ftrst-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychofic drugs in schizophrenia study ( CUt-LASS 1 ) [ J ]. Arch Gen Psychiatry, 2006, 63 (10) : 1079-1087.
  • 2牛雅娟,黄文升,郝学儒,杨甫德,吉中孚.氯氮平和利培酮治疗精神分裂症患者比较研究[J].上海精神医学,2003,15(5):276-278. 被引量:10
  • 3Janicak P G, Winans E A. Paliperidone E R: a review of the clinical trial data[ J]. Neuropsychiatr Dis Treat, 2007, 3 (6) : 869-897.
  • 4Meltzer H Y, Bobo W V, Nuamah I F, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6 week, placebo-controlled studies [ J ]. J Clin Psychiatry, 2008, 69(5):817-829.
  • 5王旸,曹昱,张艳.帕利哌酮缓释片对精神分裂症疗效及安全性的对照研究[J].精神医学杂志,2009,22(6):415-419. 被引量:91
  • 6Morosini P L, Magtiano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale( SOFAS ) to assess routine social functioning [ J ]. Acta Psvchiatr Scand. 2000. 101 (4):323-329.
  • 7Fowler J A, Bettinger T L, Argo T R. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia [ J ]. Clin Ther, 2008, 30 ( 2 ) : 231-248.
  • 8Kramer M, Simpson G, Maciulis V, et al. Paliperidone ex-tended release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study[ J]. J Clin Psyehopharmacol, 2007, 27(1) :6-14,.
  • 9Patrick D L, Burns T, Morosini P, et al. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets [J]. Clin Ther, 2010, 32(2) :275-292.
  • 10葛小锚,胡健,胡桐森.奥氮平与氯丙嗪治疗精神分裂症急性期的对照研究[J].四川精神卫生,2008,21(1):21-23. 被引量:15

二级参考文献46

  • 1Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition[J]. Am J Psychiatry, 2004, 161 (2) : 1 -56.
  • 2Canadian Psychiatric Association. Clinical practice guidelines: treatment of schizophrenia [ J]. Can J Psychiatry, 2005, 50 (1):7-57.
  • 3Grant S, Fitton A. Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia[ J ]. Drags, 1994, 48(2) : 253 -273.
  • 4Revill P, Serradell N, Bolos J. Paliperidone: antipsychotie agent treatment of bipolar disorder dual dopamine D2/5 - HT2A receptor antagonist[ J ]. Drugs Future, 2006, 31 (7) : 579 - 584.
  • 5Herbert YM, William VB, Isaax FN, et al. Efficacy and tolerability of oral paliperidone extended- release tablets in the treatment of acute schizophrenia: pooled data from three 6 - week, placebo- controlled studies [ J]. J Clin Psychiatry, 2008, 69(5) : 817 -829.
  • 6Tzimos A, Lramer M, Ford L, et al. A six - week placebo - controlled study on the safety and tolerability of flexible doses of oral paliperidone extended - release tablets in the treatment of schizophrenia in elderly patients [ C ]. 159^th Annual Meeting of the American Psychiatry Association, 2006, 183.
  • 7Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended - release tablets : a 6 - week placebo - controlled trial[ J]. Schizophrenia Research, 2007, 90( 1 ) : 147 - 161.
  • 8Lehman AF, Buchanan RW, Dickerson FB, et al. Evidence - based treatment for schizophrenia [ J ]. Psyehiatr Clin North Am, 2003, 26. 939- 954.
  • 9Lindenmayer JP, Khan A. Pharmacological treatment strategies for schizophrenia[J]. Expert Rev Neurother, 2004, 4: 705- 723.
  • 10Miller AL, Craig CS. Combination antipsychotics: pros, cons, and questions[J]. Schizophr Bull, 2002, 28: 105- 109.

共引文献113

同被引文献49

  • 1沈渔邨.精神病学[M].5版.北京:人民卫生出版社.2009:838.
  • 2中华医学会精神科分会.CCMD-3中国精神障碍分类与诊断标准[M].济南:山东科学技术出版社,2001.31-91.
  • 3中华医学会精神科分会.中国精神障碍分类与诊断标准[M].3版.济南:山东科学技术出版社,2001:108-1150.
  • 4Tiedtke P I, Bischoff C, Schmidt W J. MK-801-induced stereotypy and its antagonism by neuroleptic drugs [ J ]. Neural Transm Gen Sect, 1990, 81 (3) :173-182.
  • 5Rothman S. Noncompetitive N-methyl-D-aspartate antag- onists affect multiple ionic currents[J].Pharmacol Exp Ther, 1988, 246( 1 ) : 137-142.
  • 6Vergun O, Sobolevsky A I, Yelshansky M V, et al. Ex- ploration of the role of reactive oxygen species in gluta- mate neurotoxicity in rat hippocampal neurons in culture [ J]. Physiol, 2001, 531 ( 1 ) : 147-163.
  • 7Ahlgren H, Henjum K, Ottersen O P, et al. Validation of organotypical hippocampal slice cultures as an ex vivo model of brain ischemia- different roles of NMDA recep- tors in cell death signaling after exposure to NMDA or ox- ygen and glucose deprivation[ J]. Cell Tissue Res, 2011, 345 (3) ,329-341.
  • 8Leung J C, Ragland N, Marphis T, et al. NMDA ago- nists and antagonists induce renal culture cell toxicity [J].Med Chem. 2008. 4(6) ,565-571.
  • 9Ono T, Hashimoto E, Ukai W, et al. The role of neuralstem cells for in vitro models of schizophrenia: neuropro- tection via Akt/ERK signal regulation [ J ]. Schizophr Res, 2010, 122(1-3) :239-247.
  • 10Emamian E S, Hall D, Bimbaum M J, et al. Convergent evidence for impaired KT1-GSK3beta signaling in schizo- phrenia[J].Nat Genet,2004, 36(2) :131-137.

引证文献4

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部